Envestnet Asset Management Inc. Has $1.90 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Envestnet Asset Management Inc. increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 139.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,686 shares of the company's stock after acquiring an additional 45,791 shares during the period. Envestnet Asset Management Inc.'s holdings in Hims & Hers Health were worth $1,903,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Means Investment CO. Inc. increased its stake in Hims & Hers Health by 23.5% in the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after buying an additional 9,508 shares during the last quarter. Principal Financial Group Inc. increased its stake in Hims & Hers Health by 102.0% in the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after buying an additional 146,621 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Hims & Hers Health in the 4th quarter valued at about $2,628,000. Pacer Advisors Inc. purchased a new stake in Hims & Hers Health in the 4th quarter valued at about $374,000. Finally, Genesee Capital Advisors LLC purchased a new stake in Hims & Hers Health in the 4th quarter valued at about $889,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Bank of America increased their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research note on Tuesday, March 18th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and increased their target price for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Finally, Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $38.08.

Insiders Place Their Bets

In other news, COO Melissa Baird sold 33,333 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the transaction, the chief operating officer now directly owns 805,083 shares in the company, valued at approximately $20,755,039.74. This represents a 3.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 4,153 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $35.30, for a total value of $146,600.90. Following the transaction, the insider now owns 161,497 shares in the company, valued at $5,700,844.10. This trade represents a 2.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 712,998 shares of company stock worth $27,992,450 in the last ninety days. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Trading Down 0.1 %

HIMS opened at $28.10 on Monday. The company has a 50 day moving average of $34.24 and a 200 day moving average of $31.08. The company has a market cap of $6.24 billion, a PE ratio of 63.87 and a beta of 1.65. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.